Company History
Mucosis was founded in 2007 and is built on the proprietary Mimopath® vaccine technology platform. The technology counts its origin at the Department of Molecular Genetics at the University of Groningen and Biomade Technology Foundation, the Netherlands. The company successfully secured funding (including non-dilutive) to advance its lead program, FluGEM®, into a Phase I human clinical study in 2011 and to further develop its proprietary mucosal vaccine technology platform towards the clinic.